Effect of Danazol on Coagulation Parameters and Bleeding in Hemophilia
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
Danazol treatment in hemophiliacs shortened APTT but increased bleeding, possibly due to enhanced fibrinolytic activity, and did not consistently elevate factor activity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Danazol was given orally at a dose of 600 mg/day to six hemophiliacs for eight to 14 weeks. All patients showed a significant decrease in activated partial thromboplastin time (APTT) beginning with the first measurement (two weeks) and persisting until use of the drug was discontinued. However, a corresponding increase in the deficient factor activity could not be consistently demonstrated. Despite the shortened APTT, bleeding episodes continued in the severe hemophiliacs and the patient with Christmas disease. In four patients, bleeding appeared to increase in severity or change in pattern, and in two cases the bleeding manifestations did not respond to usual factor infusions but responded to discontinuation of the drug therapy and further factor replacement. Euglobulin lysis times were measured in five patients (one hemophiliac and four with nonhemophilic conditions) who were receiving danazol. The lysis times were markedly shortened. Increased fibrinolytic activity may be responsible for the increased bleeding manifestations in danazol-treated hemophiliacs.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (11)
- doi:10.1016/0049-3848(82)90030-5 via openalex
- doi:10.1056/nejm198306093082306 via openalex
- doi:10.1056/nejm198306093082305 via openalex
- doi:10.1136/bmj.2.6041.910 via openalex
- W2418399594 via openalex
- doi:10.3109/00365516509077275 via openalex
- doi:10.1136/bmj.281.6236.343 via openalex
- doi:10.1016/0049-3848(81)90052-9 via openalex
- doi:10.1097/00000441-195806000-00023 via openalex
- doi:10.1111/j.1365-2141.1972.tb05701.x via openalex
- doi:10.1016/0049-3848(84)90165-8 via openalex
Cited by (6)
- Danazol: <i>in vitro</i> effects on human hemopoiesis and <i>in vivo</i> activity in hypoplastic and myelodysplastic disorders 1991
- Danazol fails to increase factor VIII or IX levels in a double‐blind crossover study of patients with haemophilia A and B 1986
- Efficacy of danazol in pure red cell aplasia 1986
- Danazol in Hemophilia-Reply 1985
- Danazol in Hemophilia 1985
- Danazol and Hemophilia 1985
Source provenance
- openalex
- last seen: 2026-05-11T04:51:27.821502+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK